Primary regulatory
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA advisory committee meeting notice listing multiple peptide bulk substances scheduled for discussion.
U.S. Food and Drug AdministrationPublished 2026-07-23Accessed 2026-06-30
Registry record
Source metadata
- Publisher
- U.S. Food and Drug Administration
- Source type
- Primary regulatory
- Registry ID
fda-pcac-july-2026
Source usage
Linked from 23 pages
Compound
BPC-157
CompoundDSIP
CompoundEpitalon
CompoundKPV
CompoundMOTS-c
CompoundSemax
CompoundTB-500
ComparisonBPC-157 vs TB-500
Evidence curationBest Compounds for Longevity Research
Evidence curationBest Compounds for Mitochondrial Research
Evidence curationBest Peptides for Cognitive Enhancement
Evidence curationBest Peptides for Immune Support
Evidence curationBest Peptides for Inflammation Research
Evidence curationBest Peptides for Injury Repair
Evidence curationBest Peptides for Muscle Recovery
Evidence curationBest Peptides for Skin and Anti-Aging
Evidence curationBest Peptides for Sleep
Evidence curationBest Peptides for Stress and Anxiety Research
GuideFDA Enforcement Timeline: Major Actions on Peptides and Compounding
GuidePeptide Category Explainers: How Every Compound Class on This Site Is Defined
Research hubCompounded Peptides Explained: 503A vs 503B
Research hubRUO vs Telehealth: How People Access Peptides
Research hubWhat Does 'Research Use Only' Actually Mean?
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.